ID

29574

Description

Study ID: 104385 Clinical Study ID: RES104385 Study Title: A randomised double-blind two-period crossover study to investigate the effect of treatment with repeat doses of a PPAR gamma agonist on the allergen-induced late asthmatic response in subjects with mild asthma compared with repeat doses of placebo Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00318630 https://clinicaltrials.gov/ct2/show/NCT00318630 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: rosiglitazone Trade Name: Avandia XR,Avandia; Rosiglitazone XR,Avandia XR,Avandia Study Indication: Asthma This ODM-file contains Adverse Events: Serious Adverse Events (Part of "End of Study").

Link

https://clinicaltrials.gov/ct2/show/NCT00318630

Keywords

Versions (1)
  1. 4/6/18 4/6/18 - Sarah Riepenhausen
Copyright Holder

GlaxoSmithKline

Uploaded on

April 6, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

GSK Influence of PPAR gamma agonist vs. Placebo on allergen-induced late asthmatic response NCT00318630

English

Adverse Events: Serious Adverse Events

1 forms  
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
UMLS CUI-2
C0877248
Subject identifier
Description

Subject identifier

Data type

text

Alias
UMLS CUI [1]
C2348585
Center number
Description

Center number

Data type

text

Alias
UMLS CUI [1,1]
C1301943
UMLS CUI [1,2]
C0600091
Randomisation number
Description

Randomisation number

Data type

text

Alias
UMLS CUI [1,1]
C0034656
UMLS CUI [1,2]
C0237753
Serious Adverse Events - Section 1
Description

Serious Adverse Events - Section 1

Alias
UMLS CUI-1
C1519255
Did the subject experience a serious adverse event during the study?
Description

DEFINITION A serious adverse event is any untoward medical occurrence that, at any dose: a) results in death. b) is life-threatening. The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe. c) requires hospitalisation or prolongation of existing hospitalisation. In general, hospitalisation signifies that the subject has been detained (usually involving at least an overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or out-patient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is ’serious’. When in doubt as to whether ’hospitalisation’ occurred or was necessary, the AE should be considered ’serious’. Hospitalisation for elective treatment of a pre-existing condition that did not worsen from baseline is not considered an AE. d) results in disability/incapacity. The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption. e) is a congenital anomaly/birth defect. f) other: Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse. If yes, record the details in the other items of this itemgroup and the other Serious Adverse Events itemgroups.

Data type

text

Alias
UMLS CUI [1]
C1519255
Diagnosis only if known, otherwise sign/symptom
Description

Record one SAE diagnosis per line, or a sign/symptom if the diagnosis is not available. If a diagnosis subsequently becomes available, this then should be entered and the sign/symptom crossed out, initialled and dated by the investigator. A separate form should be used for each SAE however if multiple SAEs which are temporally or clinically related are apparent at the time of initial reporting then these may be reported on the same page. Ensure that no medical or investigational procedures are captured in the Serious Adverse Event Sections. Death should not be recorded as an SAE but should be recorded as the outcome of an SAE. The condition that resulted in the death should be recorded as the SAE.

Data type

text

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0011900
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C0037088
Start Date
Description

Record the start date of the first occurrence of the SAE. Start dates must be provided for the reporting of adverse event data. If the exact date is not known, liaise with the investigator to ensure that a best estimate is provided.

Data type

date

Alias
UMLS CUI [1]
C2697888
Start Time
Description

Record the start time of the SAE.

Data type

time

Alias
UMLS CUI [1,1]
C1301880
UMLS CUI [1,2]
C0877248
Outcome
Description

All SAEs must be followed until the events are resolved, the condition stabilises, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was ’Recovered/Resolved’ or ’Recovered/Resolved with sequelae’. If the SAE is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as ’Not recovered/Not resolved’ or ’Recovering/Resolving’. Also enter ’Not recovered/Not resolved’ if the SAE was ongoing at the time of death, but was not the cause of death. Enter fatal for the SAE which was the direct cause of death. Confirm that any SAEs marked as Recovering/Resolving or Not recovered/Not resolved have been followed up for details of resolution.

Data type

integer

Alias
UMLS CUI [1]
C1705586
End date
Description

Record the end date. This is the date the SAE Recovered/Resolved, or if the outcome was fatal, record the date the subject died (Date of Death). If the event Recovered/Resolved with sequelae, enter the date the subject’s medical condition resolved or stabilised. Leave blank if the SAE is ’Not recovered/Not resolved’ or ’Recovering/Resolving’.

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C1518404
Record the end time of the SAE.
Description

End Time

Data type

time

Alias
UMLS CUI [1]
C2826658
Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
Description

Mild = An event that is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities. Moderate = An event that is sufficiently discomforting to interfere with normal everyday activities. Severe = An event that prevents normal everyday activities. Not applicable = those event(s) where intensity is meaningless or impossible to determine (i.e., blindness and coma).

Data type

text

Alias
UMLS CUI [1]
C1710066
Action taken with investigational products as a result of the SAE
Description

Investigational product(s) withdrawn = Administration of investigational product(s) was permanently discontinued. Dose reduced = Dose is reduced for one or more investigational product(s). Dose increased = Dose increased for one or more investigational product(s). Dose not changed = Investigational product(s) continues even though an adverse event has occurred. Dose interrupted = Administration of one or more investigational product(s) was stopped temporarily but then restarted. Not applicable = Subject was not receiving investigational product(s) when the event occurred (e.g., pre-or post-dosing).

Data type

text

Alias
UMLS CUI [1]
C2826626
Did the subject withdraw from study as a result of this SAE?
Description

Indicate ’Yes’ if the event(s) were directly responsible for the subject’s withdrawal as indicated on the Study Conclusion page, otherwise indicate ’No’. If yes, complete Study Conclusion form and pick Adverse event as reason for withdrawal.

Data type

text

Alias
UMLS CUI [1,1]
C1710677
UMLS CUI [1,2]
C1519255
Is there a reasonable possibility that the SAE may have been caused by the investigational product?
Description

It is a regulatory requirement for investigators to assess relationship to investigational product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. ’A reasonable possibility’ is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence or arguments that may support ’a reasonable possibility’ include, e.g., a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge. Confounding factors, such as concomitant medication, a concurrent illness, or relevant medical history, should also be considered.

Data type

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C0439849
If fatal, was a post-mortem/autopsy performed?
Description

If Yes, summarise findings in Section 11 Narrative Remarks of the SAE itemgroups.

Data type

text

Alias
UMLS CUI [1,1]
C0004398
UMLS CUI [1,2]
C1519255
Serious Adverse Events - Section 2: Seriousness
Description

Serious Adverse Events - Section 2: Seriousness

Alias
UMLS CUI-1
C1519255
UMLS CUI-2
C0439793
SAE results in death.
Description

A

Data type

boolean

Alias
UMLS CUI [1]
C1705232
SAE Is life-threatening.
Description

B

Data type

boolean

Alias
UMLS CUI [1]
C1517874
SAE requires hospitalisation or prolongation of existing hospitalisation.
Description

C

Data type

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0019993
UMLS CUI [2,1]
C1519255
UMLS CUI [2,2]
C0745041
SAE results in disability/incapacity
Description

D

Data type

boolean

Alias
UMLS CUI [1,1]
C3176592
UMLS CUI [1,2]
C1274040
UMLS CUI [1,3]
C1519255
Congenital anomaly/birth defect
Description

E

Data type

boolean

Alias
UMLS CUI [1,1]
C0000768
UMLS CUI [1,2]
C1519255
Other
Description

F Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse. If yes, specify in the item "Other, specify".

Data type

boolean

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C1519255
Other, specify.
Description

If yes in item "other" of itemgroup SAE - Section 2: Seriousness

Data type

text

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C1519255
Serious Adverse Events - Section 3: Demography Data
Description

Serious Adverse Events - Section 3: Demography Data

Alias
UMLS CUI-1
C1828479
UMLS CUI-2
C0011298
UMLS CUI-3
C1519255
Date of birth
Description

Date of birth

Data type

date

Alias
UMLS CUI [1]
C0421451
Sex
Description

Gender

Data type

text

Alias
UMLS CUI [1]
C0079399
Weight
Description

Weight

Data type

float

Measurement units
  • kg
Alias
UMLS CUI [1]
C0005910
kg
Serious Adverse Events - Section 4
Description

Serious Adverse Events - Section 4

Alias
UMLS CUI-1
C1519255
If deliberate or inadvertent administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
Description

If Investigational Product was Stopped, Did the Reported Event(s) Recur After Further Investigational Product(s) Were Administered?

Data type

text

Alias
UMLS CUI [1,1]
C2945760
UMLS CUI [1,2]
C1519255
Serious Adverse Events - Section 5: Possible Causes of SAE Other Than Investigational Products
Description

Serious Adverse Events - Section 5: Possible Causes of SAE Other Than Investigational Products

Alias
UMLS CUI-1
C0085978
UMLS CUI-2
C1519255
UMLS CUI-3
C0304229
UMLS CUI-4
C3845511
Disease under study
Description

Disease under study

Data type

boolean

Alias
UMLS CUI [1,1]
C1547657
UMLS CUI [1,2]
C0877248
UMLS CUI [1,3]
C0012634
Medical condition(s)
Description

If yes, record in Section 6.

Data type

boolean

Alias
UMLS CUI [1,1]
C1547657
UMLS CUI [1,2]
C0877248
UMLS CUI [1,3]
C0009488
Lack of efficacy
Description

Lack of efficacy

Data type

boolean

Alias
UMLS CUI [1,1]
C1547657
UMLS CUI [1,2]
C0877248
UMLS CUI [1,3]
C0235828
Withdrawal of investigational product(s)
Description

Withdrawal of investigational product(s)

Data type

boolean

Alias
UMLS CUI [1,1]
C1547657
UMLS CUI [1,2]
C0877248
UMLS CUI [1,3]
C0304229
UMLS CUI [1,4]
C2349954
Concomitant medication
Description

If yes, record in Section 8.

Data type

boolean

Alias
UMLS CUI [1,1]
C2347852
UMLS CUI [1,2]
C1519255
UMLS CUI [1,3]
C0085978
Activity related to study participation
Description

e.g., procedures

Data type

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0085978
UMLS CUI [1,3]
C1519255
Other
Description

If yes, specify in "other, specify" item.

Data type

boolean

Alias
UMLS CUI [1,1]
C3840932
UMLS CUI [1,2]
C1519255
Other, specify
Description

If yes in item "other" of this itemgroup, specify.

Data type

text

Alias
UMLS CUI [1,1]
C3840932
UMLS CUI [1,2]
C1519255
Serious Adverse Events - Section 6: Relevant medical conditions
Description

Serious Adverse Events - Section 6: Relevant medical conditions

Alias
UMLS CUI-1
C1828479
UMLS CUI-2
C0012634
UMLS CUI-3
C1519255
Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE.
Description

Relevant past or current medical conditions

Data type

text

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C1519255
UMLS CUI [2,1]
C3899485
UMLS CUI [2,2]
C1519255
Date of onset
Description

Date of onset

Data type

date

Alias
UMLS CUI [1,1]
C0574845
UMLS CUI [1,2]
C0009488
Condition Present at Time of the SAE?
Description

Condition Present at Time of the SAE?

Data type

text

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0150312
UMLS CUI [1,3]
C1519255
If No, Date of Last Occurrence
Description

Fill in if condition was not present at time of SAE.

Data type

date

Alias
UMLS CUI [1,1]
C2745955
UMLS CUI [1,2]
C0012634
UMLS CUI [1,3]
C0011008
Serious Adverse Events - Section 7: Other relevant risk factors
Description

Serious Adverse Events - Section 7: Other relevant risk factors

Alias
UMLS CUI-1
C0035648
UMLS CUI-2
C1519255
Other RELEVANT Risk Factors
Description

Provide any family or social history (e.g., smoking, alcohol, diet, drug abuse, occupational hazard) relevant to the SAE

Data type

text

Alias
UMLS CUI [1,1]
C0035648
UMLS CUI [1,2]
C1519255
Serious Adverse Events - Section 8: Relevant concomitant medication
Description

Serious Adverse Events - Section 8: Relevant concomitant medication

Alias
UMLS CUI-1
C1519255
UMLS CUI-2
C2347852
Drug name
Description

Include details of any concomitant medication(s) which may have contributed to the event. Trade name preferred.

Data type

text

Alias
UMLS CUI [1,1]
C2360065
UMLS CUI [1,2]
C2347852
Dose
Description

Dose

Data type

float

Alias
UMLS CUI [1,1]
C3174092
UMLS CUI [1,2]
C2347852
Unit
Description

Unit

Data type

text

Alias
UMLS CUI [1,1]
C1519795
UMLS CUI [1,2]
C2347852
UMLS CUI [1,3]
C1519255
Frequency
Description

Frequency

Data type

text

Alias
UMLS CUI [1,1]
C3476109
UMLS CUI [1,2]
C2347852
UMLS CUI [1,3]
C1519255
Route
Description

Route

Data type

text

Alias
UMLS CUI [1]
C2826730
Taken prior to study?
Description

Taken prior to study?

Data type

text

Alias
UMLS CUI [1]
C2826667
Start Date
Description

Start Date

Data type

date

Alias
UMLS CUI [1]
C2826734
Stop Date
Description

Stop Date

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C2347852
Ongoing medication?
Description

Ongoing medication?

Data type

text

Alias
UMLS CUI [1]
C2826666
Reason for medication
Description

Reason for medication

Data type

text

Alias
UMLS CUI [1]
C2826696
Serious Adverse Events - Section 9: Details of investigational Products
Description

Serious Adverse Events - Section 9: Details of investigational Products

Alias
UMLS CUI-1
C1519255
UMLS CUI-2
C0304229
Start Date Treatment period 1
Description

Start Date Treatment period 1

Data type

date

Alias
UMLS CUI [1,1]
C3173309
UMLS CUI [1,2]
C0304229
Start Date Treatment period 2
Description

Start Date Treatment period 2

Data type

date

Alias
UMLS CUI [1,1]
C3173309
UMLS CUI [1,2]
C0304229
Stop Date Treatment period 1
Description

Stop Date Treatment period 1

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0304229
Stop Date Treatment period 2
Description

Stop Date Treatment period 2

Data type

date

Alias
UMLS CUI [1,1]
C0806020
UMLS CUI [1,2]
C0304229
Was treatment blind broken at investigational site?
Description

Treatment blind

Data type

text

Alias
UMLS CUI [1,1]
C2347038
UMLS CUI [1,2]
C0449438
Serious Adverse Events - Section 10: Details of relevant assessments
Description

Serious Adverse Events - Section 10: Details of relevant assessments

Alias
UMLS CUI-1
C2700391
UMLS CUI-2
C0011900
UMLS CUI-3
C1519255
Details of relevant assessments
Description

Provide details of any other tests/procedures which were carried out to diagnose or confirm the SAE e.g., laboratory data with units and normal range

Data type

text

Alias
UMLS CUI [1,1]
C2700391
UMLS CUI [1,2]
C0011900
UMLS CUI [1,3]
C1519255
Serious Adverse Events - Section 11: Narrative Remarks
Description

Serious Adverse Events - Section 11: Narrative Remarks

Alias
UMLS CUI-1
C0947611
UMLS CUI-2
C1519255
Provide a brief narrative description of the SAE and details of treatment given
Description

Narrative Remarks

Data type

text

Alias
UMLS CUI [1,1]
C0947611
UMLS CUI [1,2]
C1519255
Investigator's signature
Description

confirming that the data on the SAE pages are accurate and complete

Data type

text

Alias
UMLS CUI [1]
C2346576
Date of Investigator signature
Description

Date of Investigator signature

Data type

date

Alias
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Investigator's Name (print)
Description

Investigator's Name

Data type

text

Alias
UMLS CUI [1]
C2826892
Back to the top of the page

Similar models

Adverse Events: Serious Adverse Events

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
C0877248 (UMLS CUI-2)
Subject identifier
Item
Subject identifier
text
C2348585 (UMLS CUI [1])
Center number
Item
Center number
text
C1301943 (UMLS CUI [1,1])
C0600091 (UMLS CUI [1,2])
Randomisation number
Item
Randomisation number
text
C0034656 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
Item Group
Serious Adverse Events - Section 1
C1519255 (UMLS CUI-1)
Item
Did the subject experience a serious adverse event during the study?
text
C1519255 (UMLS CUI [1])
Non-Serious Adverse Event
Code List
Did the subject experience a serious adverse event during the study?
CL Item
yes (Y)
CL Item
no (N)
Event: Diagnosis, Signs, Symptoms
Item
Diagnosis only if known, otherwise sign/symptom
text
C0877248 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C0877248 (UMLS CUI [2,1])
C0037088 (UMLS CUI [2,2])
Start Date
Item
Start Date
date
C2697888 (UMLS CUI [1])
Start Time
Item
Start Time
time
C1301880 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
Item
Outcome
integer
C1705586 (UMLS CUI [1])
Outcome
Code List
Outcome
CL Item
Recovered/Resolved (1)
CL Item
Recovering/Resolving (2)
CL Item
Not recovered/Not resolved (3)
CL Item
Recovered/Resolved with sequelae (4)
CL Item
Fatal (5)
End Date
Item
End date
date
C0806020 (UMLS CUI [1,1])
C1518404 (UMLS CUI [1,2])
End Time
Item
Record the end time of the SAE.
time
C2826658 (UMLS CUI [1])
Item
Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
text
C1710066 (UMLS CUI [1])
Maximum intensity
Code List
Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
not applicable (X)
Item
Action taken with investigational products as a result of the SAE
text
C2826626 (UMLS CUI [1])
Action taken with investigational products
Code List
Action taken with investigational products as a result of the SAE
CL Item
investigational products withdrawn (1)
CL Item
dose reduced (2)
CL Item
dose increased (3)
CL Item
dose not changed (4)
CL Item
dose interrupted (5)
CL Item
not applicable (X)
Item
Did the subject withdraw from study as a result of this SAE?
text
C1710677 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Non-Serious Adverse Event
Code List
Did the subject withdraw from study as a result of this SAE?
CL Item
yes (Y)
CL Item
no (N)
Item
Is there a reasonable possibility that the SAE may have been caused by the investigational product?
text
C1519255 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Non-Serious Adverse Event
Code List
Is there a reasonable possibility that the SAE may have been caused by the investigational product?
CL Item
yes (Y)
CL Item
no (N)
Item
If fatal, was a post-mortem/autopsy performed?
text
C0004398 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Non-Serious Adverse Event
Code List
If fatal, was a post-mortem/autopsy performed?
CL Item
yes (Y)
CL Item
no (N)
Item Group
Serious Adverse Events - Section 2: Seriousness
C1519255 (UMLS CUI-1)
C0439793 (UMLS CUI-2)
Death
Item
SAE results in death.
boolean
C1705232 (UMLS CUI [1])
Life-threatening
Item
SAE Is life-threatening.
boolean
C1517874 (UMLS CUI [1])
(Prolongation of) Hospitalisation
Item
SAE requires hospitalisation or prolongation of existing hospitalisation.
boolean
C1519255 (UMLS CUI [1,1])
C0019993 (UMLS CUI [1,2])
C1519255 (UMLS CUI [2,1])
C0745041 (UMLS CUI [2,2])
Disability, Incapacity
Item
SAE results in disability/incapacity
boolean
C3176592 (UMLS CUI [1,1])
C1274040 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Congenital anomaly/birth defect
Item
Congenital anomaly/birth defect
boolean
C0000768 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Other
Item
Other
boolean
C0205394 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Other
Item
Other, specify.
text
C0205394 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Item Group
Serious Adverse Events - Section 3: Demography Data
C1828479 (UMLS CUI-1)
C0011298 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
Date of birth
Item
Date of birth
date
C0421451 (UMLS CUI [1])
Item
Sex
text
C0079399 (UMLS CUI [1])
Gender
Code List
Sex
CL Item
Male (Male)
CL Item
Female (Female)
Weight
Item
Weight
float
C0005910 (UMLS CUI [1])
Item Group
Serious Adverse Events - Section 4
C1519255 (UMLS CUI-1)
Item
If deliberate or inadvertent administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
text
C2945760 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Recurrent SAE after further administration
Code List
If deliberate or inadvertent administration of further dose(s) of investigational product(s) to the subject occurred, did the reported adverse event recur?
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
Unknown at this time (Unknown at this time)
CL Item
Not applicable (Not applicable)
Item Group
Serious Adverse Events - Section 5: Possible Causes of SAE Other Than Investigational Products
C0085978 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
C0304229 (UMLS CUI-3)
C3845511 (UMLS CUI-4)
Disease under study
Item
Disease under study
boolean
C1547657 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
Medical condition(s)
Item
Medical condition(s)
boolean
C1547657 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
Lack of efficacy
Item
Lack of efficacy
boolean
C1547657 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
C0235828 (UMLS CUI [1,3])
Withdrawal of investigational product(s)
Item
Withdrawal of investigational product(s)
boolean
C1547657 (UMLS CUI [1,1])
C0877248 (UMLS CUI [1,2])
C0304229 (UMLS CUI [1,3])
C2349954 (UMLS CUI [1,4])
Concomitant medication
Item
Concomitant medication
boolean
C2347852 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,3])
Activity related to study participation
Item
Activity related to study participation
boolean
C2348568 (UMLS CUI [1,1])
C0085978 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Other
Item
Other
boolean
C3840932 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Other
Item
Other, specify
text
C3840932 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Item Group
Serious Adverse Events - Section 6: Relevant medical conditions
C1828479 (UMLS CUI-1)
C0012634 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
Relevant past or current medical conditions
Item
Specify any RELEVANT past or current medical disorders, allergies, surgeries, etc. that can help explain the SAE.
text
C0262926 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
C3899485 (UMLS CUI [2,1])
C1519255 (UMLS CUI [2,2])
Date of onset
Item
Date of onset
date
C0574845 (UMLS CUI [1,1])
C0009488 (UMLS CUI [1,2])
Item
Condition Present at Time of the SAE?
text
C0012634 (UMLS CUI [1,1])
C0150312 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Non-Serious Adverse Event
Code List
Condition Present at Time of the SAE?
CL Item
yes (Y)
CL Item
no (N)
Date of Last Occurrence
Item
If No, Date of Last Occurrence
date
C2745955 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
Item Group
Serious Adverse Events - Section 7: Other relevant risk factors
C0035648 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
Other RELEVANT Risk Factors
Item
Other RELEVANT Risk Factors
text
C0035648 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Item Group
Serious Adverse Events - Section 8: Relevant concomitant medication
C1519255 (UMLS CUI-1)
C2347852 (UMLS CUI-2)
Drug name
Item
Drug name
text
C2360065 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Dose
Item
Dose
float
C3174092 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Unit
Item
Unit
text
C1519795 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Frequency
Item
Frequency
text
C3476109 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Route
Item
Route
text
C2826730 (UMLS CUI [1])
Item
Taken prior to study?
text
C2826667 (UMLS CUI [1])
Non-Serious Adverse Event
Code List
Taken prior to study?
CL Item
yes (Y)
CL Item
no (N)
Start Date
Item
Start Date
date
C2826734 (UMLS CUI [1])
Stop Date
Item
Stop Date
date
C0806020 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
Item
Ongoing medication?
text
C2826666 (UMLS CUI [1])
Non-Serious Adverse Event
Code List
Ongoing medication?
CL Item
yes (Y)
CL Item
no (N)
Reason for medication
Item
Reason for medication
text
C2826696 (UMLS CUI [1])
Item Group
Serious Adverse Events - Section 9: Details of investigational Products
C1519255 (UMLS CUI-1)
C0304229 (UMLS CUI-2)
Start Date Treatment period 1
Item
Start Date Treatment period 1
date
C3173309 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Start Date Treatment period 2
Item
Start Date Treatment period 2
date
C3173309 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Stop Date Treatment period 1
Item
Stop Date Treatment period 1
date
C0806020 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Stop Date Treatment period 2
Item
Stop Date Treatment period 2
date
C0806020 (UMLS CUI [1,1])
C0304229 (UMLS CUI [1,2])
Item
Was treatment blind broken at investigational site?
text
C2347038 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Treatment blind
Code List
Was treatment blind broken at investigational site?
CL Item
Yes (Yes)
CL Item
No (No)
CL Item
Not Applicable (Not Applicable)
Item Group
Serious Adverse Events - Section 10: Details of relevant assessments
C2700391 (UMLS CUI-1)
C0011900 (UMLS CUI-2)
C1519255 (UMLS CUI-3)
Details of relevant assessments
Item
Details of relevant assessments
text
C2700391 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Item Group
Serious Adverse Events - Section 11: Narrative Remarks
C0947611 (UMLS CUI-1)
C1519255 (UMLS CUI-2)
Narrative Remarks
Item
Provide a brief narrative description of the SAE and details of treatment given
text
C0947611 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
Investigator's signature
Item
Investigator's signature
text
C2346576 (UMLS CUI [1])
Date of Investigator signature
Item
Date of Investigator signature
date
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Investigator's Name
Item
Investigator's Name (print)
text
C2826892 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial